[CAS NO. 30299-08-2] Clinofibrate

Name: Clinofibrate
Brand: Arctom Scientific
SKU: SLK-S2664

Ships within

Stock

Price

Qty

Total

$0.00

Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis

request a quote

If there is no stock, or you need other sizes or custom synthesis, please:

PRODUCTS SPECIFICATIONS [30299-08-2]

Store

Catalog

SLK-S2664

Brand

Selleck

CAS

30299-08-2

DESCRIPTION [30299-08-2]

Overview

MDL	MFCD00865769
Molecular Weight	468.58
Molecular Formula	C28H36O6
SMILES	O(C(C(O)=O)(CC)C)C1=CC=C(C2(CCCCC2)C3=CC=C(OC(C(O)=O)(CC)C)C=C3)C=C1

For research use only.

Storage

3 years,-20°C,powder
1 years,-80°C,in solvent

Shipping

Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)

Preparing Stock Solutions

Concentration Volume Mass	1 mg	5 mg	10 mg
1 mM	2.1341 mL	10.6705 mL	21.3411 mL
5 mM	0.4268 mL	2.1341 mL	4.2682 mL
10 mM	0.2134 mL	1.0671 mL	2.1341 mL
50 mM	0.0427 mL	0.2134 mL	0.4268 mL

Description

Clinofibrate inhibits with of 0.47 mM, is a lipid-lowering agent used for controlling high cholesterol and triacylglyceride levels in the blood.

Targets

HMGCR ^[1]

0.47 mM

In vitro

Clinofibrate is an antihyperlipidemic agent with IC50 with 40 μM on the activities of human liver 3α-hydroxysteroid dehydrogenases. Clinofibrate stimulates the activity of AKR 1C4 by 2.0-fold. The concentration of Clinofibrate at which maximum stimulation is achieved is 50 μM.

In vivo

Clinofibrate significantly decreases the high plasma cholesterol level of atherosclerotic rats, which is 823 +/- 256 (mean +/- SD) mg/dl, or about ten times that of control rats (85 +/- 11 mg/dl). On treatment with Clinofibrate, the cholesterol level is reduced mostly in the very low density lipoprotein (VLDL) fraction (d less than 1.006). Heparin-releasable lipoprotein lipase activity in epididymal adipose tissue, lipoprotein lipase activity in post heparin plasma, and VLDL-triolein hydrolizing activity in adipose tissue stromal vessels are higher in Clinofibrate-treated rats than in atherosclerotic rats. Of the enzymes in the arterial wall concerned with cholesterol ester metabolism, acid cholesterol esterase activity is decreased in atherosclerotic rats, and Clinofibrate treatment increased this activity. The ratio of acyl-CoA cholesterol acyltransferase activity (ACAT) to neutral cholesterol esterase activity is higher in atherosclerotic rats than in control rats and is lower in Clinofibrate-treated rats than in atherosclerotic rats.

References

[1] Matsuura K, et al, J Pharmacol Exp Ther, 1998, 285(3), 1096-1103.
[2] Shirai K, et al, Artery, 1983, 12(3), 145-155.

Synonyms

Butanoic acid, 2,2′-[cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methyl-

2,2′-[Cyclohexylidenebis(4,1-phenyleneoxy)]bis[2-methylbutanoic acid]

1,1-Bis[4′-(1′′-carboxy-1′′-methylpropoxy)phenyl]cyclohexane

S 8527

Clinofibrate

Lipoclin